Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...
15don MSN
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Investor's Business Daily on MSN17d
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of ...
This was the stock's third consecutive day of gains.
GlobalData on MSN14d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warningsVertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback